242 related articles for article (PubMed ID: 15358133)
21. Protein kinase CK2 phosphorylates the cell cycle regulatory protein Geminin.
Kulartz M; Hiller E; Kappes F; Pinna LA; Knippers R
Biochem Biophys Res Commun; 2004 Mar; 315(4):1011-7. PubMed ID: 14985113
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of CK2 activity provokes different responses in hormone-sensitive and hormone-refractory prostate cancer cells.
Hessenauer A; Montenarh M; Götz C
Int J Oncol; 2003 Jun; 22(6):1263-70. PubMed ID: 12738992
[TBL] [Abstract][Full Text] [Related]
23. Anti-neoplastic effect of protein kinase CK2 inhibitor, 2-dimethylamino-4,5,6,7-tetrabromobenzimidazole (DMAT), on growth and hormonal activity of human adrenocortical carcinoma cell line (H295R) in vitro.
Lawnicka H; Kowalewicz-Kulbat M; Sicinska P; Kazimierczuk Z; Grieb P; Stepien H
Cell Tissue Res; 2010 May; 340(2):371-9. PubMed ID: 20383646
[TBL] [Abstract][Full Text] [Related]
24. Novel small molecule protein kinase CK2 inhibitors exert potent antitumor effects on T98G and SEGA cells in vitro.
Pucko E; Ostrowski R; Matyja E
Folia Neuropathol; 2019; 57(3):239-248. PubMed ID: 31588710
[TBL] [Abstract][Full Text] [Related]
25. Phosphorylation of Nrf2 in the transcription activation domain by casein kinase 2 (CK2) is critical for the nuclear translocation and transcription activation function of Nrf2 in IMR-32 neuroblastoma cells.
Apopa PL; He X; Ma Q
J Biochem Mol Toxicol; 2008 Feb; 22(1):63-76. PubMed ID: 18273910
[TBL] [Abstract][Full Text] [Related]
26. Tetraiodobenzimidazoles are potent inhibitors of protein kinase CK2.
Gianoncelli A; Cozza G; Orzeszko A; Meggio F; Kazimierczuk Z; Pinna LA
Bioorg Med Chem; 2009 Oct; 17(20):7281-9. PubMed ID: 19748274
[TBL] [Abstract][Full Text] [Related]
27. Selectivity analysis of protein kinase CK2 inhibitors DMAT, TBB and resorufin in cisplatin-induced stress responses.
Fritz G; Issinger OG; Olsen BB
Int J Oncol; 2009 Nov; 35(5):1151-7. PubMed ID: 19787270
[TBL] [Abstract][Full Text] [Related]
28. Inhibitory effect and its kinetic analysis of tyrphostin AG1478 on recombinant human protein kinase CK2 holoenzyme.
Liu XG; Liang NC
Acta Pharmacol Sin; 2002 Jun; 23(6):556-61. PubMed ID: 12060532
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and mechanism of anti-tumor action of new potential CK2 inhibitors toward glioblastoma cells.
Kaminska B; Ellert-Miklaszewska A; Oberbek A; Wisniewski P; Kaza B; Makowska M; Bretner M; Kazimierczuk Z
Int J Oncol; 2009 Nov; 35(5):1091-100. PubMed ID: 19787263
[TBL] [Abstract][Full Text] [Related]
30. [Inhibitory effect of AG1109 on recombinant human protein kinase CK2 holoenzyme].
Liu XG; Liang NC
Ai Zheng; 2002 Feb; 21(2):153-7. PubMed ID: 12479065
[TBL] [Abstract][Full Text] [Related]
31. Synthesis of novel polybrominated benzimidazole derivatives-potential CK2 inhibitors with anticancer and proapoptotic activity.
Łukowska-Chojnacka E; Wińska P; Wielechowska M; Poprzeczko M; Bretner M
Bioorg Med Chem; 2016 Feb; 24(4):735-41. PubMed ID: 26778657
[TBL] [Abstract][Full Text] [Related]
32. Synergistic anti-leukemic effects of CK2 inhibitors and pentabromobenzylisothioureas in vitro.
Koronkiewicz M; Chilmonczyk Z; Kazimierczuk Z
Anticancer Res; 2013 Nov; 33(11):4891-9. PubMed ID: 24222126
[TBL] [Abstract][Full Text] [Related]
33. [Inhibitory effect and kinetic analysis of sodium quercetin-7,4'-disulphate on recombinant human protein kinase CK2 holoenzyme].
Liu XG; Liang NC; Liu W; She J; Mo LE
Yao Xue Xue Bao; 2002 Mar; 37(3):165-8. PubMed ID: 12579753
[TBL] [Abstract][Full Text] [Related]
34. Selectivity of 4,5,6,7-tetrabromobenzimidazole as an ATP-competitive potent inhibitor of protein kinase CK2 from various sources.
Zień P; Bretner M; Zastapiło K; Szyszka R; Shugar D
Biochem Biophys Res Commun; 2003 Jun; 306(1):129-33. PubMed ID: 12788077
[TBL] [Abstract][Full Text] [Related]
35. Toward the rational design of protein kinase casein kinase-2 inhibitors.
Sarno S; Moro S; Meggio F; Zagotto G; Dal Ben D; Ghisellini P; Battistutta R; Zanotti G; Pinna LA
Pharmacol Ther; 2002; 93(2-3):159-68. PubMed ID: 12191608
[TBL] [Abstract][Full Text] [Related]
36. Identification of ellagic acid as potent inhibitor of protein kinase CK2: a successful example of a virtual screening application.
Cozza G; Bonvini P; Zorzi E; Poletto G; Pagano MA; Sarno S; Donella-Deana A; Zagotto G; Rosolen A; Pinna LA; Meggio F; Moro S
J Med Chem; 2006 Apr; 49(8):2363-6. PubMed ID: 16610779
[TBL] [Abstract][Full Text] [Related]
37. Differential regulation of mouse equilibrative nucleoside transporter 1 (mENT1) splice variants by protein kinase CK2.
Bone DB; Robillard KR; Stolk M; Hammond JR
Mol Membr Biol; 2007; 24(4):294-303. PubMed ID: 17520485
[TBL] [Abstract][Full Text] [Related]
38. New inhibitors of protein kinase CK2, analogues of benzimidazole and benzotriazole.
Bretner M; Najda-Bernatowicz A; Łebska M; Muszyńska G; Kilanowicz A; Sapota A
Mol Cell Biochem; 2008 Sep; 316(1-2):87-9. PubMed ID: 18548199
[TBL] [Abstract][Full Text] [Related]
39. Polyhalogenobenzimidazoles: synthesis and their inhibitory activity against casein kinases.
Andrzejewska M; Pagano MA; Meggio F; Brunati AM; Kazimierczuk Z
Bioorg Med Chem; 2003 Sep; 11(18):3997-4002. PubMed ID: 12927861
[TBL] [Abstract][Full Text] [Related]
40. Structural features underlying selective inhibition of protein kinase CK2 by ATP site-directed tetrabromo-2-benzotriazole.
Battistutta R; De Moliner E; Sarno S; Zanotti G; Pinna LA
Protein Sci; 2001 Nov; 10(11):2200-6. PubMed ID: 11604527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
